Branford drug developer Marinus Pharmaceuticals Inc. says it has gotten positive results for an anti-seizure compound it is developing to treat epileptics and other patients.
Privately held Marinus Pharma says its neurosteroid ganaxolone recently completed its followup open-label study to its Phase 2 clinical trial. Results were presented at the 65th annual meeting of the American Epilepsy Society in early December, the company said. Â
Patients in the study showed an overall decrease of 23 percent in median weekly seizure frequency from baseline of the Phase 2 study.
The ganaxolone is meant to supplement traditional anti-seizure medications, such as lamotrigine, levetiracetam, carbamazepine and topiramate.Â
Seventy percent of subjects had an improvement in their seizures, with minimal side effects, during the study, and one quarter had an improvement of 50 percent or more compared to baseline of the double-blind study, Marinus said.Â
Founded in 2003, Marinus is focused on commercializing ganaxolone to treat epilepsy, post-traumatic stress disorder and fragile-X syndrome, a genetic syndrome associated with autism.
